Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 105.35% is 286% above its 5-year average of -56.74%, near the high end of its 5-year range (-96.79%–105.35%).
As of the fiscal period ended Tuesday, June 30, 2026. 1415.32% above its 12-month average of 6.95%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 105.35%.
RETURN ON EQUITY (ROE)
105.35%
RETURN ON EQUITY (ROE) AVG TTM
6.95%
RETURN ON EQUITY (ROE) AVG 3Y
-69.32%
RETURN ON EQUITY (ROE) AVG 5Y
-56.74%
RETURN ON EQUITY (ROE) AVG 10Y
-55.31%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+1415.32%
CURRENT VS 3Y AVG
+251.98%
CURRENT VS 5Y AVG
+285.68%
CURRENT VS 10Y AVG
+290.46%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.94%
median of 399 covered companies
CURRENT VS SECTOR MEDIAN
+385.21%
vs the sector median at left
Enlivex Therapeutics Ltd.
Market Cap
$6.09M
Return on Equity (ROE)
105.35%
TTM Avg
6.95%
3Y Avg
-69.32%
5Y Avg
-56.74%
Market Cap
$6.10M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
Market Cap
$6.10M
Return on Equity (ROE)
-304.78%
TTM Avg
-566.96%
3Y Avg
-321.57%
5Y Avg
-251.82%
Market Cap
$6.03M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
23.75%
Market Cap
$6.34M
Return on Equity (ROE)
-143.54%
TTM Avg
-132.34%
3Y Avg
-104.07%
5Y Avg
-91.90%
Market Cap
$6.44M
Return on Equity (ROE)
N/A
TTM Avg
-266.00%
3Y Avg
851.50%
5Y Avg
629.05%
Market Cap
$5.63M
Return on Equity (ROE)
-92.08%
TTM Avg
-1221.97%
3Y Avg
-730.41%
5Y Avg
-532.44%
Market Cap
$5.54M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
Market Cap
$6.72M
Return on Equity (ROE)
-227.37%
TTM Avg
-118.13%
3Y Avg
-87.25%
5Y Avg
-55.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enlivex Therapeutics Ltd. (ENLV) | $6.09M | 105.35% | 6.95% | -69.32% | -56.74% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -87.12% | -90.45% | -143.11% | -272.17% |
| Femasys Inc. (FEMY)vs › | $6.10M | -304.78% | -566.96% | -321.57% | -251.82% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -92.44% | -28.72% | 10.69% | 23.75% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -143.54% | -132.34% | -104.07% | -91.90% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | N/A | -266.00% | 851.50% | 629.05% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | -92.08% | -1221.97% | -730.41% | -532.44% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | -225.57% | -289.16% | -245.03% | -192.04% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -227.37% | -118.13% | -87.25% | -55.09% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -54.09% | -388.62% | -105.04% | -44.72% |
ROE
105.4%
ROA
83.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 105.35% |
| 2025-12-31 | 63.85% |
| 2025-09-30 | -72.66% |
| 2025-06-30 | -68.74% |
| 2025-03-31 | -69.45% |
| 2024-12-31 | -63.65% |
| 2024-09-30 | -71.21% |
| 2024-06-30 | -78.05% |
| 2024-03-31 | -96.79% |
| 2023-12-31 | -96.62% |
| 2023-09-30 | -70.04% |
| 2023-06-30 | -60.75% |
| 2023-03-31 | -59.42% |
| 2022-12-31 | -54.64% |
| 2022-09-30 | -45.21% |
| 2022-06-30 | -38.40% |
| 2022-03-31 | -25.10% |
| 2021-12-31 | -17.01% |
| 2021-09-30 | -17.71% |
| 2021-06-30 | -15.85% |
| 2021-03-31 | -15.71% |
| 2020-12-31 | -33.32% |
| 2020-09-30 | -30.97% |
| 2020-06-30 | -30.12% |
| 2020-03-31 | -23.43% |
| 2019-12-31 | -83.18% |
| 2019-09-30 | -58.78% |
| 2019-06-30 | -44.35% |
| 2019-03-31 | -43.72% |
| 2018-12-31 | -43.72% |
| 2018-09-30 | -28.91% |
| 2018-06-30 | -204.87% |
| 2018-03-31 | -48.64% |
| 2017-12-31 | -188.01% |
| 2017-09-30 | -225.55% |
| 2017-06-30 | -255.15% |
| 2017-03-31 | -224.95% |
| 2016-12-31 | -184.18% |
| 2016-09-30 | -156.35% |
| 2016-06-30 | -107.57% |
| 2016-03-31 | -82.56% |
| 2015-12-31 | -85.68% |
| 2015-09-30 | -61.91% |
| 2015-06-30 | -48.74% |
| 2015-03-31 | -34.44% |
| 2014-12-31 | -22.89% |
| 2014-09-30 | -14.60% |
| 2014-06-30 | -77.87% |
